Literature DB >> 29463882

The genetics of recurrent hydatidiform moles: new insights and lessons from a comprehensive analysis of 113 patients.

Ngoc Minh Phuong Nguyen1, Yassemine Khawajkie2, Nawel Mechtouf1, Maryam Rezaei1, Magali Breguet3, Elvira Kurvinen4, Sujatha Jagadeesh5, Asli Ece Solmaz6, Monica Aguinaga7, Reda Hemida8, Mehmet Ibrahim Harma9, Cécile Rittore10, Kurosh Rahimi11, Jocelyne Arseneau12, Karine Hovanes13, Ronald Clisham14, Tiffanee Lenzi15, Bonnie Scurry16, Marie-Claude Addor17, Rashmi Bagga18, Genevieve Girardet Nendaz19, Vildana Finci20, Gemma Poke21, Leslie Grimes22, Nerine Gregersen23, Kayla York24, Pierre-Adrien Bolze25, Chirag Patel26, Hossein Mozdarani27, Jacques Puechberty28, Jessica Scotchie29, Majid Fardaei30, Muge Harma9, R J McKinlay Gardner21,31, Trilochan Sahoo13, Tracy Dudding-Byth32, Radhika Srinivasan33, Philippe Sauthier3, Rima Slim34,35,36.   

Abstract

Hydatidiform mole is an aberrant human pregnancy characterized by early embryonic arrest and excessive trophoblastic proliferation. Recurrent hydatidiform moles are defined by the occurrence of at least two hydatidiform moles in the same patient. Fifty to eighty percent of patients with recurrent hydatidiform moles have biallelic pathogenic variants in NLRP7 or KHDC3L. However, in the remaining patients, the genotypic types of the moles are unknown. We characterized 80 new hydatidiform mole tissues, 57 of which were from patients with no mutations in the known genes, and we reviewed the genotypes of a total of 123 molar tissues. We also reviewed mutation analysis in 113 patients with recurrent hydatidiform moles. While all hydatidiform moles from patients with biallelic NLRP7 or KHDC3L mutations are diploid biparental, we demonstrate that those from patients without mutations are highly heterogeneous and only a small minority of them are diploid biparental (8%). The other mechanisms that were found to recur in patients without mutations are diploid androgenetic monospermic (24%) and triploid dispermic (32%); the remaining hydatidiform moles were misdiagnosed as moles due to errors in the analyses and/or their unusual mechanisms. We compared three parameters of genetic susceptibility in patients with and without mutations and show that patients without mutations are mostly from non-familial cases, have fewer reproductive losses, and more live births. Our data demonstrate that patients with recurrent hydatidiform moles and no mutations in the known genes are, in general, different from those with mutations; they have a milder genetic susceptibility and/or a multifactorial etiology underlying their recurrent hydatidiform moles. Categorizing these patients according to the genotypic types of their recurrent hydatidiform moles may facilitate the identification of novel genes for this entity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29463882     DOI: 10.1038/s41379-018-0031-9

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

Review 1.  Genetics of human female infertility†.

Authors:  Svetlana A Yatsenko; Aleksandar Rajkovic
Journal:  Biol Reprod       Date:  2019-09-01       Impact factor: 4.285

2.  NLRP7 variants in spontaneous abortions with multilocus imprinting disturbances from women with recurrent pregnancy loss.

Authors:  Elena A Sazhenova; Tatyana V Nikitina; Stanislav A Vasilyev; Ekaterina N Tolmacheva; Oksana Yu Vasilyeva; Anton V Markov; Sergey Yu Yuryev; Nikolay A Skryabin; Alexey A Zarubin; Nikita A Kolesnikov; Vadim A Stepanov; Igor N Lebedev
Journal:  J Assist Reprod Genet       Date:  2021-09-23       Impact factor: 3.412

3.  Association of extended culture to blastocyst and pre-malignant gestational trophoblastic disease risk following IVF/ICSI-assisted reproduction cycles: an analysis of large UK national database.

Authors:  B G I K Bambaranda; R Bomiriya; P Mehlawat; M Choudhary
Journal:  J Assist Reprod Genet       Date:  2022-08-24       Impact factor: 3.357

4.  Causative Mutations and Mechanism of Androgenetic Hydatidiform Moles.

Authors:  Ngoc Minh Phuong Nguyen; Zhao-Jia Ge; Ramesh Reddy; Somayyeh Fahiminiya; Philippe Sauthier; Rashmi Bagga; Feride Iffet Sahin; Sangeetha Mahadevan; Matthew Osmond; Magali Breguet; Kurosh Rahimi; Louise Lapensee; Karine Hovanes; Radhika Srinivasan; Ignatia B Van den Veyver; Trilochan Sahoo; Asangla Ao; Jacek Majewski; Teruko Taketo; Rima Slim
Journal:  Am J Hum Genet       Date:  2018-11-01       Impact factor: 11.025

5.  Application of next-generation sequencing to preimplantation genetic testing for recurrent hydatidiform mole patients.

Authors:  Jingyi Yang; Zhiqiang Yan; Yan Liu; Xiaohui Zhu; Rong Li; Ping Liu; Liying Yan; Jie Qiao; Xu Zhi
Journal:  J Assist Reprod Genet       Date:  2021-10-04       Impact factor: 3.412

6.  The genetics of recurrent hydatidiform moles in Mexico: further evidence of a strong founder effect for one mutation in NLRP7 and its widespread.

Authors:  Mónica Aguinaga; Maryam Rezaei; Irma Monroy; Nawel Mechtouf; Javier Pérez; Elsa Moreno; Yolotzin Valdespino; Carolina Galaz; Guadalupe Razo; Daniela Medina; Raúl Piña; Rima Slim
Journal:  J Assist Reprod Genet       Date:  2021-03-22       Impact factor: 3.357

7.  Molar and nonmolar triploidy: Recurrence or bad luck.

Authors:  Brianne Robinson; Jo-Ann Brock; Craig Midgen; Jillian Coolen
Journal:  Clin Case Rep       Date:  2020-02-11

8.  Collaboration Benefits All.

Authors:  Reda A Hemida; Helena C van Doorn; Leon F A G Massuger
Journal:  JCO Glob Oncol       Date:  2020-02

9.  Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases.

Authors:  Deyin Xing; Emily Adams; Jialing Huang; Brigitte M Ronnett
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

10.  Loss of p57 Expression in Conceptions Other Than Complete Hydatidiform Mole: A Case Series With Emphasis on the Etiology, Genetics, and Clinical Significance.

Authors:  Deyin Xing; Karin Miller; Katie Beierl; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2022-01-01       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.